...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Contemporary ob/gyn >Patients who need mifepristone must find a clinician who stocks it in the office
【24h】

Patients who need mifepristone must find a clinician who stocks it in the office

机译：需要米非司酮的患者必须在办公室找到股票的临床医生

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Strangely, mifepristone has never been shown to pose risks warranting REMS. This was evidenced recently by the FDA, which in 2016 approved an updated label for the drug that, among other things, removed language that the prescribed must be a physician and eliminated the requirement to report nonfatal adverse events. And yet, this requirement prevents prescription sales in retail pharmacies. In other words, patients who need mifepristone-for any indication or reason, be it a medical abortion, medical management of EPL or uterine fibroids-must find a clinician who stocks mifepristone in the office. This is not an easy task. According to Danco, the manufacturer of Mifeprex, only 7% of sales nationwide were to private medical practices. Reluctance to stock the drug is thought to be widespread and reasons may include concerns about ordering, managing and dispensing a drug; costs (both of drug as well as related to wasted doses due to expiration prior to use); the burden of excessive paperwork; and, of course, stigma associated with use of mifepristone for induced medical abortion. All these factors jeopardize women's access to our profession's evidence-based standards of care.
机译：奇怪的是，米非司酮从未被证明是有保证REM的风险。最近由FDA证明，2016年，2016年批准了该药物的更新标签，其中包括所列必须是医生并消除报告非缺乏事件的要求。然而，这一要求防止了零售药房的处方销售。换句话说，需要米非司酮的患者 - 对于任何指示或理性，是它的医疗流产，EPL或子宫肌瘤的医疗管理 - 必须找到植物在办公室的米非司代代。这不是一项简单的任务。据米飞德克快乐制造商据Danco介绍，全国仅有7％的销售额为私人医疗惯例。储存的不愿意普遍认为是普遍的，原因可能包括对订购，管理和分配药物的担忧;成本（药物的两者以及由于在使用前的到期而与浪费剂量有关）;过度文书工作的负担;当然，当然，与使用米非司酮相关的耻辱对于诱导医用流产。所有这些因素都危及妇女对我们专业的循证护理标准的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号